Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval ...

Gilead is the latest drugmaker to announce that it’s pouring billions of dollars into its manufacturing and R&D operations in ...

Teva is planning to reduce its headcount by 8% by 2027, the company announced on Wednesday, as it enters the next phase of ...

A leading pharmaceutical trade group urged the Department of Commerce not to place tariffs on the sector as the window for ...